Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
17/07/2026 06:10
July 17 (Reuters) - Camurus ABCAMX.ST : * NDA RESUBMISSION FOR CAM2029 IN ACROMEGALY ACCEPTED FOR REVIEW BY THE US FDA Source text:ID:nWkr2HVs1 Further company coverage:CAMX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat